Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTLP1N)

• Drug Name: Combinectin Drug Info
• Synonyms: GSK3732394

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMTLP1N

Molecule-Related Drug Atlas

Drug(s) Targeting Human immunodeficiency virus Glycoprotein 41 (HIV gp41)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enfuvirtide	DM7YPM1	Human immunodeficiency virus infection	1C62	Approved	[3]
Sifuvirtide	DMMIWCE	Human immunodeficiency virus infection	1C62	Phase 3	[4]
ITV-1	DMCJX79	Human immunodeficiency virus infection	1C62	Phase 2	[5]
T-1249	DMB2NP8	Human immunodeficiency virus infection	1C62	Phase 1/2	[6]
MaC46/M87o	DMIRG15	Human immunodeficiency virus-1 infection	1C62	Phase 1/2	[7]
Multi-envelope HIV vaccine	DMAGCHE	Human immunodeficiency virus infection	1C62	Phase 1	[8]
Gp41 HIV-1 vaccine	DM9JV80	Human immunodeficiency virus infection	1C62	Phase 1	[9]

Drug(s) Targeting T-cell surface glycoprotein CD4 (CD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibalizumab	DMV67QO	Human immunodeficiency virus infection	1C62	Approved	[10]
TNX-355	DMYA41S	Human immunodeficiency virus infection	1C62	Phase 3	[11]
Zanolimumab	DMKB4ZY	Lymphoma	2A80-2A86	Phase 3	[12]
Magrolimab	DMVXUR0	Acute myeloid leukaemia	2A60	Phase 3	[13]
Fluoropeptide vaccine	DMCEUOH	Influenza virus infection	1E30-1E32	Phase 2	[14]
BT-061	DM2LZIY	Asthma	CA23	Phase 2	[15]
LIPO-4	DMJRALD	Human immunodeficiency virus infection	1C62	Phase 1	[16]
TMB-365	DMH3E5C	Human immunodeficiency virus-1 infection	1C62	Phase 1	[17]
CD4CAR	DM09SW6	T-cell leukaemia	2A90	Phase 1	[18]
VRC07-523LS	DM0S9OT	Human immunodeficiency virus-1 infection	1C62	Phase 1	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Glycoprotein 41 (HIV gp41)	TTG90S6	ENV_HV1H2	Inhibitor	[2]
T-cell surface glycoprotein CD4 (CD4)	TTN2JFW	CD4_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03984812) Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of ViiV Healthcare.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.J Biol Chem.2012 Feb 24;287(9):6788-96.
• [5] Clinical pipeline report, company report or official report of Immunotech Laboratories.
• [6] HIV entry inhibitors in clinical development. Curr Opin Pharmacol. 2002 Oct;2(5):523-8.
• [7] DOI: 10.1038/mt.sj.6300124
• [8] An assessment of the role of chimpanzees in AIDS vaccine research. Altern Lab Anim. 2008 Sep;36(4):381-428.
• [9] Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617.
• [10] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [11] Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
• [12] Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007 Jun 1;109(11):4655-62.
• [13] Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791.
• [14] A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402.
• [15] Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunol Cell Biol.2015 Apr;93(4):321-2.
• [16] Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15.
• [17] Clinical pipeline report, company report or official report of TaiMed Biologics.
• [18] Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
• [19] Clinical pipeline report, company report or official report of TaiMed Biologics.